STOKE THERAPEUTICS INC (STOK) — insider trading
Health Care · NASDAQ
STOKE THERAPEUTICS INC (STOK) has 50 reported SEC Form 4 insider transactions in our data, including 18 open-market sales among the most recent 50 (latest 2026-10-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Allan Jonathan | Officer (GENERAL COUNSEL & CORP SEC) | Open-market sale | 627 | $26.33 | $16.5K | Form 4 |
| 2026-10-01 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 1,051 | $26.16 | $27.5K | Form 4 |
| 2026-09-23 | Cumbo Alexander | Director | Grant / award / vesting (derivative) | 39,674 | — | $0 | Form 4 |
| 2026-09-01 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 1,600 | $31.06 | $49.7K | Form 4 |
| 2026-09-01 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 3,945 | $30.51 | $120.4K | Form 4 |
| 2026-08-18 | Allan Jonathan | Officer (GENERAL COUNSEL & CORP SEC) | Open-market sale | 145 | $32.47 | $4.7K | Form 4 |
| 2026-08-18 | Allan Jonathan | Officer (GENERAL COUNSEL & CORP SEC) | Open-market sale | 2,716 | $32.01 | $86.9K | Form 4 |
| 2026-08-18 | Kaye Edward M. MD | Director | Open-market sale | 637 | $32.47 | $20.7K | Form 4 |
| 2026-08-18 | Kaye Edward M. MD | Director | Open-market sale | 11,930 | $32.01 | $381.8K | Form 4 |
| 2026-08-18 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 242 | $32.47 | $7.9K | Form 4 |
| 2026-08-18 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 4,525 | $32.01 | $144.8K | Form 4 |
| 2026-08-14 | Allan Jonathan | Officer (GENERAL COUNSEL & CORP SEC) | Option exercise / conversion (derivative) | 6,000 | — | $0 | Form 4 |
| 2026-08-14 | Allan Jonathan | Officer (GENERAL COUNSEL & CORP SEC) | Option exercise / conversion | 6,000 | — | $0 | Form 4 |
| 2026-08-14 | Kaye Edward M. MD | Director | Option exercise / conversion (derivative) | 26,250 | — | $0 | Form 4 |
| 2026-08-14 | Kaye Edward M. MD | Director | Option exercise / conversion | 26,250 | — | $0 | Form 4 |
| 2026-08-14 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-08-14 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 10,000 | — | $0 | Form 4 |
| 2026-08-03 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 1,269 | $29.45 | $37.4K | Form 4 |
| 2026-08-03 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 5,907 | $28.95 | $171.0K | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 17,786 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 17,786 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 29,747 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 29,747 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 7,639 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 7,639 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 19,441 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 19,441 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 21,000 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 21,000 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 11,650 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 11,650 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 14,777 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 14,777 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 29,555 | — | $0 | Form 4 |
| 2026-07-16 | Harrison Seth Loring | Director | Bona fide gift (derivative) | 29,555 | — | $0 | Form 4 |
| 2026-07-15 | McCauley Thomas | Officer (Chief Scientific Officer) | Grant / award / vesting (derivative) | 225,000 | — | $0 | Form 4 |
| 2026-07-01 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 500 | $33.27 | $16.6K | Form 4 |
| 2026-07-01 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 6,728 | $32.62 | $219.4K | Form 4 |
| 2026-06-16 | Allan Jonathan | Officer (GENERAL COUNSEL & CORP SEC) | Open-market sale | 1,457 | $29.95 | $43.6K | Form 4 |
| 2026-06-03 | Burstein Jennifer | Director | Grant / award / vesting (derivative) | 17,786 | — | $0 | Form 4 |
| 2026-06-03 | Harrison Seth Loring | Director | Grant / award / vesting (derivative) | 17,786 | — | $0 | Form 4 |
| 2026-06-03 | Kaye Edward M. MD | Director | Grant / award / vesting (derivative) | 17,786 | — | $0 | Form 4 |
| 2026-06-03 | Krainer Adrian R. | Director | Grant / award / vesting (derivative) | 17,786 | — | $0 | Form 4 |
| 2026-06-03 | LEVIN ARTHUR A | Director | Grant / award / vesting (derivative) | 17,786 | — | $0 | Form 4 |
| 2026-06-03 | Smith Julie | Director | Grant / award / vesting (derivative) | 17,786 | — | $0 | Form 4 |
| 2026-06-03 | TZIANABOS ARTHUR | Director | Grant / award / vesting (derivative) | 17,786 | — | $0 | Form 4 |
| 2026-06-01 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 1,795 | $30.58 | $54.9K | Form 4 |
| 2026-05-01 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 2,243 | $32.79 | $73.5K | Form 4 |
| 2026-04-03 | Kahn Clare | Director | Grant / award / vesting (derivative) | 30,782 | — | $0 | Form 4 |
| 2026-04-01 | Ticho Barry | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 1,838 | $32.66 | $60.0K | Form 4 |
Ask the chat about STOK's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: STOKE THERAPEUTICS INC (STOK).
Last updated 2026-10-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.